The companies will work together to produce a wearable device that can subcutaneously deliver ketamine therapy as a non-opioid pain treatment.
Stevanato Group, an Italian glass primary packaging producer, announced on Sept. 21, 2020 that it has signed an agreement with Bexson Biomedical, a research-stage company, for the development of the SG EZ-be Pod, a wearable drug delivery device for Bexson’s proprietary ketamine formulation, BB106.
Under the terms of the agreement, the companies will work together to produce a small, wearable and programable device that can subcutaneously deliver the ketamine therapy to patients looking for a non-opioid treatment for chronic and acute pain types, a Stevanato press release said.
“In the midst of a pandemic health crisis and evidence of increasing opioid addiction and overdoses, there has never been a greater need for effective non-opioid pain management. Stevanato Group has the ideal technology to deliver Bexson’s BB106 subcutaneous ketamine formulation,” said Gregg Peterson, Bexson’s co-founder and CEO, in the press release. “And beyond pain management, this partnership will create a true ketamine delivery platform that can be leveraged for a large number of future indications.”
“This design will support patient comfort with a discreet and intuitive device, and by utilizing our patented technologies, we address the importance of sustainability, while minimizing the overall cost per treatment,” said Steven Kaufman, vice-president of Drug Delivery Systems, Stevanato Group, in the press release. “This agreement with Bexson is a step forward for our device portfolio strategy and ongoing efforts to work closely with biotech and pharmaceutical companies as an integrated solution provider.”
Source: Stevanato
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.